$BRGX
BIOREGENX, INC. Stock $brgx

$brgx Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000168316824007026 Filed on October 09, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024 Q1
Revenue	$596.0K	$734.0K	$618.1K
YoY Change	16052.76%	9152.89%	11033.29%
Cost Of Revenue	$114.4K	$264.2K	$159.4K
YoY Change			22664.29%
Gross Profit	$481.6K	$469.9K	$458.8K
YoY Change	12952.79%	5825.32%	9359.18%
Gross Profit Margin	80.81%	64.01%	74.22%
Selling, General & Admin	$236.3K	$835.0K	$1.096M
YoY Change	6037.12%	9735.08%	1039.75%
% of Gross Profit	49.06%	177.71%	238.8%
Research & Development	$0.00	$7.500K
YoY Change	-100.0%	-90.72%
% of Gross Profit	0.0%	1.6%
Depreciation & Amortization	$12.38K	$7.642K	$200.1K
YoY Change	178.13%	412.89%	13420.27%
% of Gross Profit	2.57%	1.63%	43.62%
Operating Expenses	$809.0K	$1.510M	$1.096M
YoY Change	15063.17%	15033.07%	1014.41%
Operating Profit	-$327.3K	-$1.040M	-$636.8K
YoY Change	19797.08%	50795.59%	586.5%
Interest Expense			-$68.04K
YoY Change			-3423.89%
% of Operating Profit
Other Income/Expense, Net	-$67.55K	-$66.33K
YoY Change	3201.71%	3081.34%
Pretax Income			-$704.8K
YoY Change			28.61%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$394.9K	-$1.106M	-$704.8K
YoY Change	10597.91%	26695.74%	28.61%
Net Earnings / Revenue	-66.25%	-150.69%	-114.02%
Basic Earnings Per Share	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	956.5M shares	956.6M shares
Diluted Shares Outstanding	956.5M shares	956.5M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$70.08K	$57.40K
Short-Term Investments
Other Short-Term Assets	$73.32K	$108.7K
YoY Change
Inventory	$158.7K	$143.9K
Prepaid Expenses	$5.162K	$5.162K
Receivables	$19.44K	$10.94K
Other Receivables
Total Short-Term Assets	$371.0K	$326.1K
YoY Change	48849.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$213.1K	$225.5K
YoY Change
Goodwill	$7.106M	$7.106M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change
Total Long-Term Assets	$16.99M	$17.56M
YoY Change	51040.25%	20442.17%
TOTAL ASSETS
Total Short-Term Assets	$371.0K	$326.1K
Total Long-Term Assets	$16.99M	$17.56M
Total Assets	$17.36M	$17.89M
YoY Change	50991.39%	20823.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$492.7K	$431.8K
YoY Change	1784.9%	1628.62%
Accrued Expenses	$426.7K	$398.1K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.518M	$3.420M
YoY Change	1362.72%	8090.32%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.518M	$3.420M
Total Long-Term Liabilities
Total Liabilities	$3.801M	$3.670M
YoY Change	1480.07%	1444.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.17M	-$16.78M
YoY Change	391.41%	387.71%
Common Stock	$956.5K	$956.5K
YoY Change	245.63%	245.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.56M	$14.22M	$15.09M
YoY Change
Total Liabilities & Shareholders Equity	$17.36M	$17.89M
YoY Change	50991.39%	20823.52%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$394.9K	-$1.106M	-$704.8K
YoY Change	10597.91%	26695.74%	28.61%
Depreciation, Depletion And Amortization	$12.38K	$7.642K	$200.1K
YoY Change	178.13%	412.89%	13420.27%
Cash From Operating Activities			$38.07K
YoY Change			-6826.15%
INVESTING ACTIVITIES
Capital Expenditures			$19.04M
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			-$19.04M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$18.44M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			18.99M
YoY Change			-17261090.91%
NET CHANGE
Cash From Operating Activities			38.07K
Cash From Investing Activities			-19.04M
Cash From Financing Activities			18.99M
Net Change In Cash			-11.25K
YoY Change			1564.2%
FREE CASH FLOW
Cash From Operating Activities			$38.07K
Capital Expenditures			$19.04M
Free Cash Flow			-$19.00M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56345
	dei	Entity Registrant Name EntityRegistrantName	BIOREGENX, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Registrant Name EntityRegistrantName	BIOREGENX, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-1912453
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7407 Ziegler Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chattanooga
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37421
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	770-4067
	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57395	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125402	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	143924	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	217529	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113815	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205152	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	326077	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	652664	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	225493	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13723	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10233776	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49363	usd
CY2024Q2	us-gaap	Goodwill Goodwill	7105522	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	150000	usd
CY2024Q2	us-gaap	Assets Assets	17890868	usd
CY2023Q4	us-gaap	Assets Assets	865750	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	431810	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	241695	usd
CY2024Q2	brgx	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	196517	usd
CY2023Q4	brgx	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	213516	usd
CY2024Q2	brgx	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	351603	usd
CY2023Q4	brgx	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	292190	usd
CY2024Q2	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	522500	usd
CY2023Q4	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	322500	usd
CY2024Q2	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	850813	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	375681	usd
CY2024Q2	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	995294	usd
CY2023Q4	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	963215	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	195938	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	354203	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3420033	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2787177	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	249599	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2937177	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	30-1912453
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7407 Ziegler Road
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chattanooga
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37421
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	770-4067
	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	956530100	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57395	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125402	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10943	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	217529	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113815	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205152	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	326077	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	652664	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	225493	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13723	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10233776	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49363	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	150000	usd
CY2024Q2	us-gaap	Assets Assets	17890868	usd
CY2023Q4	us-gaap	Assets Assets	865750	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	431810	usd
CY2024Q2	brgx	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	196517	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	398058	usd
CY2024Q2	brgx	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	351603	usd
CY2023Q4	brgx	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	292190	usd
CY2024Q2	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	522500	usd
CY2023Q4	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	322500	usd
CY2024Q2	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	850813	usd
CY2024Q2	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	995294	usd
CY2023Q4	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	963215	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	195938	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	354203	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3420033	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2787177	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	249599	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	150000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2937177	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125402	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10943	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	104581	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	143924	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	217529	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113815	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205152	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	326077	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	652664	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	225493	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13723	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10233776	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49363	usd
CY2024Q2	us-gaap	Goodwill Goodwill	7105522	usd
CY2023Q4	us-gaap	Goodwill Goodwill	0	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	150000	usd
CY2024Q2	us-gaap	Assets Assets	17890868	usd
CY2023Q4	us-gaap	Assets Assets	865750	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	431810	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	241695	usd
CY2024Q2	brgx	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	196517	usd
CY2023Q4	brgx	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	213516	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	398058	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	346677	usd
CY2024Q2	brgx	Accrued Interest Related Party Current AccruedInterestRelatedPartyCurrent	351603	usd
CY2023Q4	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	322500	usd
CY2024Q2	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	850813	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	375681	usd
CY2024Q2	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	995294	usd
CY2023Q4	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	963215	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	195938	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3420033	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2787177	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	249599	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	150000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	3669632	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2937177	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	956530100	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	956530100	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	770833296	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	770833296	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	956530	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	770833	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30040648	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	956530100	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	956530100	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	770833296	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	956530	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	770833	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9676656	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16776564	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12517978	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	618	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-942	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	14221236	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	865750	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
	brgx	Gross Sales GrossSales	1542483	usd
	brgx	Gross Sales GrossSales	1986438	usd
CY2024Q2	brgx	Returns Returns	123502	usd
CY2023Q2	us-gaap	Revenues Revenues	863278	usd
	us-gaap	Revenues Revenues	1283580	usd
	us-gaap	Revenues Revenues	1938862	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	264967	usd
	us-gaap	Cost Of Revenue CostOfRevenue	429544	usd
	us-gaap	Cost Of Revenue CostOfRevenue	576661	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	469878	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	598311	usd
CY2024Q2	brgx	Distributors Incentives DistributorsIncentives	112588	usd
CY2023Q2	brgx	Distributors Incentives DistributorsIncentives	142596	usd
	brgx	Distributors Incentives DistributorsIncentives	167246	usd
	brgx	Distributors Incentives DistributorsIncentives	319600	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	834998	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1000334	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3746163	usd
CY2024Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	562089	usd
CY2023Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1059860	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1509675	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1142930	usd
	us-gaap	Operating Expenses OperatingExpenses	2090926	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1039797	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-544619	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4119233	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-728725	usd
CY2024Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2	usd
CY2024Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	66331	usd
CY2023Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	49843	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	956530100	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	770833296	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	770833296	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	770833	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30040648	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9676656	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16776564	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12517978	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	618	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-942	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	14221236	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17890868	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	865750	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
	brgx	Gross Sales GrossSales	1986438	usd
CY2024Q2	brgx	Returns Returns	123502	usd
CY2023Q2	brgx	Returns Returns	19510	usd
	brgx	Returns Returns	258903	usd
	brgx	Returns Returns	47576	usd
CY2023Q2	us-gaap	Revenues Revenues	863278	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	264154	usd
	us-gaap	Cost Of Revenue CostOfRevenue	429544	usd
	us-gaap	Cost Of Revenue CostOfRevenue	576661	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	469878	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	598311	usd
	us-gaap	Gross Profit GrossProfit	854036	usd
	us-gaap	Gross Profit GrossProfit	1362201	usd
CY2024Q2	brgx	Distributors Incentives DistributorsIncentives	112588	usd
CY2023Q2	brgx	Distributors Incentives DistributorsIncentives	142596	usd
	brgx	Distributors Incentives DistributorsIncentives	167246	usd
	brgx	Distributors Incentives DistributorsIncentives	319600	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	834998	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1000334	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3746163	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1771326	usd
CY2024Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	562089	usd
CY2023Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1059860	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1509675	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1142930	usd
	us-gaap	Operating Expenses OperatingExpenses	4973269	usd
	us-gaap	Operating Expenses OperatingExpenses	2090926	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-544619	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4119233	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-728725	usd
CY2024Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2	usd
CY2024Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	66331	usd
	us-gaap	Financing Interest Expense FinancingInterestExpense	139353	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	30040648	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9676656	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16776564	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12517978	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	618	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	14221236	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17890868	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	865750	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
	brgx	Gross Sales GrossSales	1986438	usd
CY2024Q2	brgx	Returns Returns	123502	usd
CY2023Q2	brgx	Returns Returns	19510	usd
	brgx	Returns Returns	258903	usd
	brgx	Returns Returns	47576	usd
CY2024Q2	us-gaap	Revenues Revenues	734032	usd
CY2023Q2	us-gaap	Revenues Revenues	863278	usd
	us-gaap	Revenues Revenues	1283580	usd
	us-gaap	Revenues Revenues	1938862	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	264154	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	264967	usd
	us-gaap	Cost Of Revenue CostOfRevenue	429544	usd
	us-gaap	Cost Of Revenue CostOfRevenue	576661	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	598311	usd
	us-gaap	Gross Profit GrossProfit	854036	usd
	us-gaap	Gross Profit GrossProfit	1362201	usd
CY2024Q2	brgx	Distributors Incentives DistributorsIncentives	112588	usd
CY2023Q2	brgx	Distributors Incentives DistributorsIncentives	142596	usd
	brgx	Distributors Incentives DistributorsIncentives	319600	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	834998	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1000334	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3746163	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1771326	usd
CY2024Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	562089	usd
CY2023Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1059860	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1509675	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1142930	usd
	us-gaap	Operating Expenses OperatingExpenses	4973269	usd
	us-gaap	Operating Expenses OperatingExpenses	2090926	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1039797	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4119233	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-728725	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
CY2024Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	66331	usd
CY2023Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	49843	usd
	us-gaap	Financing Interest Expense FinancingInterestExpense	139353	usd
	us-gaap	Financing Interest Expense FinancingInterestExpense	95576	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-66331	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-49842	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-139353	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	9676656	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16776564	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12517978	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	618	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-942	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	14221236	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	865750	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
CY2023Q2	brgx	Gross Sales GrossSales	882788	usd
	brgx	Gross Sales GrossSales	1986438	usd
CY2024Q2	brgx	Returns Returns	123502	usd
	brgx	Returns Returns	47576	usd
CY2024Q2	us-gaap	Revenues Revenues	734032	usd
CY2023Q2	us-gaap	Revenues Revenues	863278	usd
	us-gaap	Revenues Revenues	1283580	usd
	us-gaap	Revenues Revenues	1938862	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	264154	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	264967	usd
	us-gaap	Cost Of Revenue CostOfRevenue	429544	usd
	us-gaap	Cost Of Revenue CostOfRevenue	576661	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	469878	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	598311	usd
CY2024Q2	brgx	Distributors Incentives DistributorsIncentives	112588	usd
CY2023Q2	brgx	Distributors Incentives DistributorsIncentives	142596	usd
	brgx	Distributors Incentives DistributorsIncentives	167246	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	834998	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1000334	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3746163	usd
CY2024Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	562089	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1059860	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1509675	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1142930	usd
	us-gaap	Operating Expenses OperatingExpenses	4973269	usd
	us-gaap	Operating Expenses OperatingExpenses	2090926	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1039797	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4119233	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-728725	usd
CY2024Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2	usd
CY2024Q2	us-gaap	Financing Interest Expense FinancingInterestExpense	66331	usd
	us-gaap	Financing Interest Expense FinancingInterestExpense	139353	usd
	us-gaap	Financing Interest Expense FinancingInterestExpense	95576	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-66331	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-49842	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-95574	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	956530100	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	956530100	shares
	us-gaap	Financing Interest Expense FinancingInterestExpense	139353	usd
	us-gaap	Financing Interest Expense FinancingInterestExpense	95576	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-66331	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-49842	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-95574	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1106128	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	956530100	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	764300475	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	762007141	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	762007141	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1106128	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	518	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19732	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1105610	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-579523	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4257026	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-804567	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2527938	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	751843	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	689569	usd
	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServices	1823136	usd
	brgx	Stock Issued During Period Fair Value Of Common Shares And Warrants Issued For Refunds StockIssuedDuringPeriodFairValueOfCommonSharesAndWarrantsIssuedForRefunds	41551	usd
	brgx	Issuance Of Common Shares And Warrants As Loan Incentive IssuanceOfCommonSharesAndWarrantsAsLoanIncentive	20839	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10656000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	7318594	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1560	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	14221236	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2415246	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	414107	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14938	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2580662	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	67833	usd
CY2024Q2	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServices	172854	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1106128	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	519	usd
	us-gaap	Financing Interest Expense FinancingInterestExpense	95576	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-66331	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-49842	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-139353	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-95574	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	956530100	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	956530100	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	764300475	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	956530100	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	762007141	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1106128	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1560	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19732	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1105610	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4257026	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-804567	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2527938	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	751843	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19732	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2580662	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	689569	usd
	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServices	1823136	usd
	brgx	Stock Issued During Period Fair Value Of Common Shares And Warrants Issued For Refunds StockIssuedDuringPeriodFairValueOfCommonSharesAndWarrantsIssuedForRefunds	41551	usd
	brgx	Issuance Of Common Shares And Warrants As Loan Incentive IssuanceOfCommonSharesAndWarrantsAsLoanIncentive	20839	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10656000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	7318594	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1560	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2415246	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	414107	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14938	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2580662	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	67833	usd
CY2024Q2	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServices	172854	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1106128	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	519	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	24801	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	brgx	Fair Value Of Option Issued To Officers And Directors For Services FairValueOfOptionIssuedToOfficersAndDirectorsForServices	1823136	usd
	brgx	Fair Value Of Option Issued To Officers And Directors For Services FairValueOfOptionIssuedToOfficersAndDirectorsForServices	0	usd
	brgx	Fair Value Of Common Shares Issued For Services FairValueOfCommonSharesIssuedForServices	689569	usd
	brgx	Fair Value Of Common Shares Issued For Services FairValueOfCommonSharesIssuedForServices	0	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-95574	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	956530100	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	956530100	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	764300475	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	764300475	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	956530100	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	956530100	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	762007141	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	762007141	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1106128	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	518	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19732	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1105610	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4257026	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-804567	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19732	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2580662	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	689569	usd
	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServices	1823136	usd
	brgx	Stock Issued During Period Fair Value Of Common Shares And Warrants Issued For Refunds StockIssuedDuringPeriodFairValueOfCommonSharesAndWarrantsIssuedForRefunds	41551	usd
	brgx	Issuance Of Common Shares And Warrants As Loan Incentive IssuanceOfCommonSharesAndWarrantsAsLoanIncentive	20839	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10656000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	7318594	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1560	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2415246	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	414107	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14938	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2580662	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	15085299	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	67833	usd
CY2024Q2	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServices	172854	usd
CY2024Q2	brgx	Issuance Of Common Shares And Warrants As Loan Incentive IssuanceOfCommonSharesAndWarrantsAsLoanIncentive	859	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1106128	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	519	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	14221236	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1070261	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	764300475	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	764300475	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	956530100	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	956530100	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	762007141	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	762007141	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	518	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	14938	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19732	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1105610	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-579523	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4257026	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-804567	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	19732	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2580662	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2071427	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	689569	usd
	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServices	1823136	usd
	brgx	Stock Issued During Period Fair Value Of Common Shares And Warrants Issued For Refunds StockIssuedDuringPeriodFairValueOfCommonSharesAndWarrantsIssuedForRefunds	41551	usd
	brgx	Issuance Of Common Shares And Warrants As Loan Incentive IssuanceOfCommonSharesAndWarrantsAsLoanIncentive	20839	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	10656000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	7318594	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1560	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	414107	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-594461	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14938	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-2580662	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	15085299	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	67833	usd
CY2024Q2	brgx	Stock Issued During Period Fair Value Of Options Issued To Officers And Directors For Services StockIssuedDuringPeriodFairValueOfOptionsIssuedToOfficersAndDirectorsForServices	172854	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1106128	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	519	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Income Loss NetIncomeLoss	-824299	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1070261	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2387	usd
	brgx	Fair Value Of Option Issued To Officers And Directors For Services FairValueOfOptionIssuedToOfficersAndDirectorsForServices	1823136	usd
	brgx	Fair Value Of Common Shares Issued For Services FairValueOfCommonSharesIssuedForServices	0	usd
	brgx	Fair Value Of Warrants Issued For Refunds FairValueOfWarrantsIssuedForRefunds	19351	usd
	brgx	Fair Value Of Warrants Issued For Refunds FairValueOfWarrantsIssuedForRefunds	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-93638	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2884	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-73605	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2387	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	brgx	Fair Value Of Option Issued To Officers And Directors For Services FairValueOfOptionIssuedToOfficersAndDirectorsForServices	1823136	usd
	brgx	Fair Value Of Common Shares Issued For Services FairValueOfCommonSharesIssuedForServices	0	usd
	brgx	Fair Value Of Warrants Issued For Refunds FairValueOfWarrantsIssuedForRefunds	19351	usd
	brgx	Fair Value Of Warrants Issued For Refunds FairValueOfWarrantsIssuedForRefunds	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-93638	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2884	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-73605	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	76833	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-91337	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	51680	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	190115	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-387333	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-16999	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-62949	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5167	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	124528	usd
	brgx	Increase Decrease In Accrued Liabilities And Other Operating Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilitiesRelatedParties	59413	usd
	brgx	Increase Decrease In Accrued Liabilities And Other Operating Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilitiesRelatedParties	59310	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-136065	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	228032	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281591	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-985953	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	189390	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2652	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	brgx	Cash Acquired In Docsun Transaction CashAcquiredInDocsunTransaction	1445	usd
	brgx	Cash Acquired In Docsun Transaction CashAcquiredInDocsunTransaction	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-190597	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-29458	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-177000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	400000	usd
	brgx	Increase In Note And Loan Balances Related Parties IncreaseInNoteAndLoanBalancesRelatedParties	32079	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	751844	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	402621	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1560	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19732	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-68007	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-391377	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125402	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	616696	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	225319	usd
	us-gaap	Interest Paid InterestPaid	36621	usd
	us-gaap	Interest Paid InterestPaid	53814	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	brgx	Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. FairValueOfCommonStockIssuedForIntangiblePropertyAndEquipmentInAcquisitionOfDocsunBiomedicalHoldingsInc.	10656000	usd
	brgx	Fair Value Of Common Stock Issued Upon Acquisition Of Intangible Property And Goodwill In Merger With Findit Inc. FairValueOfCommonStockIssuedUponAcquisitionOfIntangiblePropertyAndGoodwillInMergerWithFinditInc.	7318594	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue FairValueOfCommonStockAndWarrantsIssuedForRefundsOffsetToDeferredRevenue	22200	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue FairValueOfCommonStockAndWarrantsIssuedForRefundsOffsetToDeferredRevenue	0	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2387	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	brgx	Fair Value Of Option Issued To Officers And Directors For Services FairValueOfOptionIssuedToOfficersAndDirectorsForServices	1823136	usd
	brgx	Fair Value Of Common Shares Issued For Services FairValueOfCommonSharesIssuedForServices	0	usd
	brgx	Fair Value Of Warrants Issued For Refunds FairValueOfWarrantsIssuedForRefunds	19351	usd
	brgx	Fair Value Of Warrants Issued For Refunds FairValueOfWarrantsIssuedForRefunds	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-93638	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2884	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-73605	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	76833	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-91337	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	51680	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	190115	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-16999	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-62949	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5167	usd
	brgx	Increase Decrease In Accrued Liabilities And Other Operating Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilitiesRelatedParties	59413	usd
	brgx	Increase Decrease In Accrued Liabilities And Other Operating Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilitiesRelatedParties	59310	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-136065	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	228032	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281591	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2652	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	brgx	Cash Acquired In Docsun Transaction CashAcquiredInDocsunTransaction	1445	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-29458	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-177000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	400000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	brgx	Increase In Note And Loan Balances Related Parties IncreaseInNoteAndLoanBalancesRelatedParties	32079	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	751844	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	402621	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	574844	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1560	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19732	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-68007	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-391377	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125402	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	616696	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57395	usd
	us-gaap	Interest Paid InterestPaid	36621	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	brgx	Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. FairValueOfCommonStockIssuedForIntangiblePropertyAndEquipmentInAcquisitionOfDocsunBiomedicalHoldingsInc.	10656000	usd
	brgx	Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. FairValueOfCommonStockIssuedForIntangiblePropertyAndEquipmentInAcquisitionOfDocsunBiomedicalHoldingsInc.	0	usd
	brgx	Fair Value Of Common Stock Issued Upon Acquisition Of Intangible Property And Goodwill In Merger With Findit Inc. FairValueOfCommonStockIssuedUponAcquisitionOfIntangiblePropertyAndGoodwillInMergerWithFinditInc.	7318594	usd
	brgx	Fair Value Of Common Stock Issued Upon Acquisition Of Intangible Property And Goodwill In Merger With Findit Inc. FairValueOfCommonStockIssuedUponAcquisitionOfIntangiblePropertyAndGoodwillInMergerWithFinditInc.	0	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue FairValueOfCommonStockAndWarrantsIssuedForRefundsOffsetToDeferredRevenue	22200	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Loan Fees Offset To Loan Discounts FairValueOfCommonStockAndWarrantsIssuedForLoanFeesOffsetToLoanDiscounts	0	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	150000	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	0	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	30000	usd
	brgx	Fair Value Of Warrants Issued For Refunds FairValueOfWarrantsIssuedForRefunds	19351	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-93638	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-73605	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	76833	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-91337	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	51680	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	190115	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-387333	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-16999	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-62949	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5167	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	124528	usd
	brgx	Increase Decrease In Accrued Liabilities And Other Operating Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilitiesRelatedParties	59413	usd
	brgx	Increase Decrease In Accrued Liabilities And Other Operating Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilitiesRelatedParties	59310	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-136065	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	228032	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281591	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2652	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	brgx	Cash Acquired In Docsun Transaction CashAcquiredInDocsunTransaction	1445	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-190597	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-29458	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-177000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	400000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	brgx	Increase In Note And Loan Balances Related Parties IncreaseInNoteAndLoanBalancesRelatedParties	32079	usd
	brgx	Increase In Note And Loan Balances Related Parties IncreaseInNoteAndLoanBalancesRelatedParties	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	751844	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	402621	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	574844	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1560	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19732	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-68007	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-391377	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125402	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	616696	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57395	usd
	us-gaap	Interest Paid InterestPaid	53814	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	brgx	Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. FairValueOfCommonStockIssuedForIntangiblePropertyAndEquipmentInAcquisitionOfDocsunBiomedicalHoldingsInc.	10656000	usd
	brgx	Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. FairValueOfCommonStockIssuedForIntangiblePropertyAndEquipmentInAcquisitionOfDocsunBiomedicalHoldingsInc.	0	usd
	brgx	Fair Value Of Common Stock Issued Upon Acquisition Of Intangible Property And Goodwill In Merger With Findit Inc. FairValueOfCommonStockIssuedUponAcquisitionOfIntangiblePropertyAndGoodwillInMergerWithFinditInc.	7318594	usd
	brgx	Fair Value Of Common Stock Issued Upon Acquisition Of Intangible Property And Goodwill In Merger With Findit Inc. FairValueOfCommonStockIssuedUponAcquisitionOfIntangiblePropertyAndGoodwillInMergerWithFinditInc.	0	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue FairValueOfCommonStockAndWarrantsIssuedForRefundsOffsetToDeferredRevenue	22200	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue FairValueOfCommonStockAndWarrantsIssuedForRefundsOffsetToDeferredRevenue	0	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Loan Fees Offset To Loan Discounts FairValueOfCommonStockAndWarrantsIssuedForLoanFeesOffsetToLoanDiscounts	20839	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	150000	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	0	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	30000	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	76833	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-91337	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	51680	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	190115	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-387333	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-16999	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-62949	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5167	usd
	brgx	Increase Decrease In Accrued Liabilities And Other Operating Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilitiesRelatedParties	59413	usd
	brgx	Increase Decrease In Accrued Liabilities And Other Operating Liabilities Related Parties IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilitiesRelatedParties	59310	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-136065	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	228032	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-985953	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	189390	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2652	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	brgx	Cash Acquired In Docsun Transaction CashAcquiredInDocsunTransaction	1445	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-29458	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-177000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	400000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	brgx	Increase In Note And Loan Balances Related Parties IncreaseInNoteAndLoanBalancesRelatedParties	32079	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	751844	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	402621	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	574844	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1560	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19732	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-68007	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-391377	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125402	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	616696	usd
	us-gaap	Interest Paid InterestPaid	36621	usd
	us-gaap	Interest Paid InterestPaid	53814	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
	brgx	Fair Value Of Common Stock Issued For Intangible Property And Equipment In Acquisition Of Docsun Biomedical Holdings Inc. FairValueOfCommonStockIssuedForIntangiblePropertyAndEquipmentInAcquisitionOfDocsunBiomedicalHoldingsInc.	10656000	usd
	brgx	Fair Value Of Common Stock Issued Upon Acquisition Of Intangible Property And Goodwill In Merger With Findit Inc. FairValueOfCommonStockIssuedUponAcquisitionOfIntangiblePropertyAndGoodwillInMergerWithFinditInc.	7318594	usd
	brgx	Fair Value Of Common Stock Issued Upon Acquisition Of Intangible Property And Goodwill In Merger With Findit Inc. FairValueOfCommonStockIssuedUponAcquisitionOfIntangiblePropertyAndGoodwillInMergerWithFinditInc.	0	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue FairValueOfCommonStockAndWarrantsIssuedForRefundsOffsetToDeferredRevenue	22200	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Refunds Offset To Deferred Revenue FairValueOfCommonStockAndWarrantsIssuedForRefundsOffsetToDeferredRevenue	0	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Loan Fees Offset To Loan Discounts FairValueOfCommonStockAndWarrantsIssuedForLoanFeesOffsetToLoanDiscounts	20839	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	150000	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	0	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	30000	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	0	usd
	brgx	Fair Value Of Common Stock And Warrants Issued For Loan Fees Offset To Loan Discounts FairValueOfCommonStockAndWarrantsIssuedForLoanFeesOffsetToLoanDiscounts	20839	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	150000	usd
	brgx	Reclass Or Deposits To Intangibles ReclassOrDepositsToIntangibles	0	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	30000	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281591	usd
	brgx	Working Capital Deficit WorkingCapitalDeficit	3093956	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57395	usd
CY2024Q2	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	522500	usd
	brgx	Debt Discount Upon Issuance Of Notes Payable DebtDiscountUponIssuanceOfNotesPayable	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281591	usd
	brgx	Working Capital Deficit WorkingCapitalDeficit	3093956	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57395	usd
CY2024Q2	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	522500	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zCeXnnvFRfs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_86B_zDHoLtA5niY3">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in purchase price allocations, and assumptions made in valuing equity instruments issued for services and acquisitions. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281591	usd
	brgx	Working Capital Deficit WorkingCapitalDeficit	3093956	usd
CY2024Q2	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	522500	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4258586	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281591	usd
	brgx	Working Capital Deficit WorkingCapitalDeficit	3093956	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57395	usd
CY2024Q2	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	522500	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zCeXnnvFRfs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_86B_zDHoLtA5niY3">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in purchase price allocations, and assumptions made in valuing equity instruments issued for services and acquisitions. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
CY2023Q2	brgx	Gross Sales GrossSales	882788	usd
	brgx	Gross Sales GrossSales	1542483	usd
	brgx	Gross Sales GrossSales	1986438	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
CY2023Q2	brgx	Gross Sales GrossSales	882788	usd
	brgx	Gross Sales GrossSales	1542483	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
CY2023Q2	brgx	Gross Sales GrossSales	882788	usd
	brgx	Gross Sales GrossSales	1542483	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
CY2023Q2	brgx	Gross Sales GrossSales	882788	usd
	brgx	Gross Sales GrossSales	1542483	usd
	brgx	Gross Sales GrossSales	1986438	usd
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p id="xdx_846_eus-gaap--RevenueRecognitionDeferredRevenue_zkgXi0y6j4jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_860_ztu8x1I2CYV9">Deferred Revenue</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company as a matter of ordinary operations allocates the purchase price against the performance obligation on an order-by-order basis for the entire order. In the event an order has not been fulfilled or partially filled revenues are not recognized for the portion of the order for which the performance obligation has not been satisfied. In 2022 the company shipped packages of its new wellness product that omitted certain components. An allocation to the portion of the orders that were not fulfilled with functional units was made and deferred revenues of $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_c20221231__us-gaap--DeferredRevenueArrangementTypeAxis__custom--WellnessProductsOmittedComponentMember_z04wRLXc5ki" title="Deferred revenue for orders with omitted components">65,166</span> were recorded. In 2023, the remaining components shipped resulting in the recognition of $<span id="xdx_906_eus-gaap--RecognitionOfDeferredRevenue_c20240101__20240630__us-gaap--DeferredRevenueArrangementTypeAxis__custom--WellnessProductsOmittedComponentMember_zJTsF0MD7qPl" title="Revenue recognition for orders with omitted components">65,166</span> of revenue. The Company also made advanced shipments of certain components of its medical test machines. These components were not functional relative to the testing machine’s purpose and no revenue was recorded for these shipments. As of December 31, 2023, the Company recorded deferred revenue of $<span id="xdx_908_eus-gaap--DeferredRevenueCurrent_iI_c20231231_zF8x3hcKXmAi" title="Deferred revenue current">354,203</span>, which was net of $<span id="xdx_90D_eus-gaap--AssetsFairValueAdjustment_c20230101__20231231_zwxri4OXiUTh" title="Fair value of medical test machines potential refund">193,811</span> related to the fair value of equity instruments issued for refunds. For six months ended June 30, 2024, the functional components and all other items in certain of the testing machine packages were shipped resulting in the recognition of revenue of $<span id="xdx_90F_eus-gaap--RecognitionOfDeferredRevenue_c20240101__20240630_zbIQeiOFXK33" title="Recognition of revenue">330,645</span>, which was offset by $<span id="xdx_903_eus-gaap--AssetsFairValueAdjustment_c20240101__20240630_zEcY0juHUWGk" title="Related to the fair value of equity instruments issued for refunds">236,684</span> relating to fair value of equity instruments issued for refunds. As of June 30, 2024, the Company had deferred revenue of $<span id="xdx_906_eus-gaap--DeferredRevenueCurrent_iI_c20240630_zEBp86gqSyC1" title="Deferred revenue current">195,938</span>, which was mostly related to funds received from customers in advance of shipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
CY2023Q2	brgx	Gross Sales GrossSales	882788	usd
	brgx	Gross Sales GrossSales	1542483	usd
	brgx	Gross Sales GrossSales	1986438	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
CY2023Q2	brgx	Gross Sales GrossSales	882788	usd
	brgx	Gross Sales GrossSales	1542483	usd
	brgx	Gross Sales GrossSales	1986438	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
CY2023Q2	brgx	Gross Sales GrossSales	882788	usd
	brgx	Gross Sales GrossSales	1542483	usd
CY2024Q2	brgx	Gross Sales GrossSales	857534	usd
CY2023Q2	brgx	Gross Sales GrossSales	882788	usd
	brgx	Gross Sales GrossSales	1542483	usd
	brgx	Gross Sales GrossSales	1986438	usd
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p id="xdx_846_eus-gaap--RevenueRecognitionDeferredRevenue_zkgXi0y6j4jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_860_ztu8x1I2CYV9">Deferred Revenue</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company as a matter of ordinary operations allocates the purchase price against the performance obligation on an order-by-order basis for the entire order. In the event an order has not been fulfilled or partially filled revenues are not recognized for the portion of the order for which the performance obligation has not been satisfied. In 2022 the company shipped packages of its new wellness product that omitted certain components. An allocation to the portion of the orders that were not fulfilled with functional units was made and deferred revenues of $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_c20221231__us-gaap--DeferredRevenueArrangementTypeAxis__custom--WellnessProductsOmittedComponentMember_z04wRLXc5ki" title="Deferred revenue for orders with omitted components">65,166</span> were recorded. In 2023, the remaining components shipped resulting in the recognition of $<span id="xdx_906_eus-gaap--RecognitionOfDeferredRevenue_c20240101__20240630__us-gaap--DeferredRevenueArrangementTypeAxis__custom--WellnessProductsOmittedComponentMember_zJTsF0MD7qPl" title="Revenue recognition for orders with omitted components">65,166</span> of revenue. The Company also made advanced shipments of certain components of its medical test machines. These components were not functional relative to the testing machine’s purpose and no revenue was recorded for these shipments. As of December 31, 2023, the Company recorded deferred revenue of $<span id="xdx_908_eus-gaap--DeferredRevenueCurrent_iI_c20231231_zF8x3hcKXmAi" title="Deferred revenue current">354,203</span>, which was net of $<span id="xdx_90D_eus-gaap--AssetsFairValueAdjustment_c20230101__20231231_zwxri4OXiUTh" title="Fair value of medical test machines potential refund">193,811</span> related to the fair value of equity instruments issued for refunds. For six months ended June 30, 2024, the functional components and all other items in certain of the testing machine packages were shipped resulting in the recognition of revenue of $<span id="xdx_90F_eus-gaap--RecognitionOfDeferredRevenue_c20240101__20240630_zbIQeiOFXK33" title="Recognition of revenue">330,645</span>, which was offset by $<span id="xdx_903_eus-gaap--AssetsFairValueAdjustment_c20240101__20240630_zEcY0juHUWGk" title="Related to the fair value of equity instruments issued for refunds">236,684</span> relating to fair value of equity instruments issued for refunds. As of June 30, 2024, the Company had deferred revenue of $<span id="xdx_906_eus-gaap--DeferredRevenueCurrent_iI_c20240630_zEBp86gqSyC1" title="Deferred revenue current">195,938</span>, which was mostly related to funds received from customers in advance of shipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	354203	usd
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	193811	usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	330645	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	236684	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	195938	usd
	brgx	Gross Sales GrossSales	1986438	usd
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p id="xdx_846_eus-gaap--RevenueRecognitionDeferredRevenue_zkgXi0y6j4jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_860_ztu8x1I2CYV9">Deferred Revenue</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company as a matter of ordinary operations allocates the purchase price against the performance obligation on an order-by-order basis for the entire order. In the event an order has not been fulfilled or partially filled revenues are not recognized for the portion of the order for which the performance obligation has not been satisfied. In 2022 the company shipped packages of its new wellness product that omitted certain components. An allocation to the portion of the orders that were not fulfilled with functional units was made and deferred revenues of $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_c20221231__us-gaap--DeferredRevenueArrangementTypeAxis__custom--WellnessProductsOmittedComponentMember_z04wRLXc5ki" title="Deferred revenue for orders with omitted components">65,166</span> were recorded. In 2023, the remaining components shipped resulting in the recognition of $<span id="xdx_906_eus-gaap--RecognitionOfDeferredRevenue_c20240101__20240630__us-gaap--DeferredRevenueArrangementTypeAxis__custom--WellnessProductsOmittedComponentMember_zJTsF0MD7qPl" title="Revenue recognition for orders with omitted components">65,166</span> of revenue. The Company also made advanced shipments of certain components of its medical test machines. These components were not functional relative to the testing machine’s purpose and no revenue was recorded for these shipments. As of December 31, 2023, the Company recorded deferred revenue of $<span id="xdx_908_eus-gaap--DeferredRevenueCurrent_iI_c20231231_zF8x3hcKXmAi" title="Deferred revenue current">354,203</span>, which was net of $<span id="xdx_90D_eus-gaap--AssetsFairValueAdjustment_c20230101__20231231_zwxri4OXiUTh" title="Fair value of medical test machines potential refund">193,811</span> related to the fair value of equity instruments issued for refunds. For six months ended June 30, 2024, the functional components and all other items in certain of the testing machine packages were shipped resulting in the recognition of revenue of $<span id="xdx_90F_eus-gaap--RecognitionOfDeferredRevenue_c20240101__20240630_zbIQeiOFXK33" title="Recognition of revenue">330,645</span>, which was offset by $<span id="xdx_903_eus-gaap--AssetsFairValueAdjustment_c20240101__20240630_zEcY0juHUWGk" title="Related to the fair value of equity instruments issued for refunds">236,684</span> relating to fair value of equity instruments issued for refunds. As of June 30, 2024, the Company had deferred revenue of $<span id="xdx_906_eus-gaap--DeferredRevenueCurrent_iI_c20240630_zEBp86gqSyC1" title="Deferred revenue current">195,938</span>, which was mostly related to funds received from customers in advance of shipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	354203	usd
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	193811	usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	330645	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	236684	usd
CY2024Q2	us-gaap	Advertising Expense AdvertisingExpense	16377	usd
	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p id="xdx_846_eus-gaap--RevenueRecognitionDeferredRevenue_zkgXi0y6j4jf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_860_ztu8x1I2CYV9">Deferred Revenue</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company as a matter of ordinary operations allocates the purchase price against the performance obligation on an order-by-order basis for the entire order. In the event an order has not been fulfilled or partially filled revenues are not recognized for the portion of the order for which the performance obligation has not been satisfied. In 2022 the company shipped packages of its new wellness product that omitted certain components. An allocation to the portion of the orders that were not fulfilled with functional units was made and deferred revenues of $<span id="xdx_904_eus-gaap--DeferredRevenue_iI_c20221231__us-gaap--DeferredRevenueArrangementTypeAxis__custom--WellnessProductsOmittedComponentMember_z04wRLXc5ki" title="Deferred revenue for orders with omitted components">65,166</span> were recorded. In 2023, the remaining components shipped resulting in the recognition of $<span id="xdx_906_eus-gaap--RecognitionOfDeferredRevenue_c20240101__20240630__us-gaap--DeferredRevenueArrangementTypeAxis__custom--WellnessProductsOmittedComponentMember_zJTsF0MD7qPl" title="Revenue recognition for orders with omitted components">65,166</span> of revenue. The Company also made advanced shipments of certain components of its medical test machines. These components were not functional relative to the testing machine’s purpose and no revenue was recorded for these shipments. As of December 31, 2023, the Company recorded deferred revenue of $<span id="xdx_908_eus-gaap--DeferredRevenueCurrent_iI_c20231231_zF8x3hcKXmAi" title="Deferred revenue current">354,203</span>, which was net of $<span id="xdx_90D_eus-gaap--AssetsFairValueAdjustment_c20230101__20231231_zwxri4OXiUTh" title="Fair value of medical test machines potential refund">193,811</span> related to the fair value of equity instruments issued for refunds. For six months ended June 30, 2024, the functional components and all other items in certain of the testing machine packages were shipped resulting in the recognition of revenue of $<span id="xdx_90F_eus-gaap--RecognitionOfDeferredRevenue_c20240101__20240630_zbIQeiOFXK33" title="Recognition of revenue">330,645</span>, which was offset by $<span id="xdx_903_eus-gaap--AssetsFairValueAdjustment_c20240101__20240630_zEcY0juHUWGk" title="Related to the fair value of equity instruments issued for refunds">236,684</span> relating to fair value of equity instruments issued for refunds. As of June 30, 2024, the Company had deferred revenue of $<span id="xdx_906_eus-gaap--DeferredRevenueCurrent_iI_c20240630_zEBp86gqSyC1" title="Deferred revenue current">195,938</span>, which was mostly related to funds received from customers in advance of shipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	193811	usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	330645	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	236684	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	195938	usd
CY2024Q2	us-gaap	Advertising Expense AdvertisingExpense	16377	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	42979	usd
	us-gaap	Advertising Expense AdvertisingExpense	28079	usd
	us-gaap	Advertising Expense AdvertisingExpense	92086	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7500	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	354203	usd
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	193811	usd
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	330645	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	236684	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	195938	usd
CY2024Q2	us-gaap	Advertising Expense AdvertisingExpense	16377	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	42979	usd
	us-gaap	Advertising Expense AdvertisingExpense	28079	usd
	us-gaap	Advertising Expense AdvertisingExpense	92086	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80781	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35809	usd
CY2024Q2	us-gaap	Advertising Expense AdvertisingExpense	16377	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	42979	usd
	us-gaap	Advertising Expense AdvertisingExpense	28079	usd
	us-gaap	Advertising Expense AdvertisingExpense	92086	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80781	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35809	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7500	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80781	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35809	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	175072	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z0R9wgByY1P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zrbbPmBHkdre">Reclassifications</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the current period, the Company reclassified $<span id="xdx_902_ecustom--AccruedExpensesReclassifiedAmount_iI_c20231231_zreYFeI65dHb" title="Accrued expenses reclassified amount">72,000</span> of return reserves previously reflected as an offset to accounts receivable at December 31, 2023 to accrued expenses to conform to current period classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"></p>
CY2023Q4	brgx	Accrued Expenses Reclassified Amount AccruedExpensesReclassifiedAmount	72000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z0R9wgByY1P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zrbbPmBHkdre">Reclassifications</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the current period, the Company reclassified $<span id="xdx_902_ecustom--AccruedExpensesReclassifiedAmount_iI_c20231231_zreYFeI65dHb" title="Accrued expenses reclassified amount">72,000</span> of return reserves previously reflected as an offset to accounts receivable at December 31, 2023 to accrued expenses to conform to current period classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"></p>
CY2023Q4	brgx	Accrued Expenses Reclassified Amount AccruedExpensesReclassifiedAmount	72000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z0R9wgByY1P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zrbbPmBHkdre">Reclassifications</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the current period, the Company reclassified $<span id="xdx_902_ecustom--AccruedExpensesReclassifiedAmount_iI_c20231231_zreYFeI65dHb" title="Accrued expenses reclassified amount">72,000</span> of return reserves previously reflected as an offset to accounts receivable at December 31, 2023 to accrued expenses to conform to current period classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"></p>
CY2023Q4	brgx	Accrued Expenses Reclassified Amount AccruedExpensesReclassifiedAmount	72000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	143924	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	217529	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z0R9wgByY1P9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zrbbPmBHkdre">Reclassifications</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the current period, the Company reclassified $<span id="xdx_902_ecustom--AccruedExpensesReclassifiedAmount_iI_c20231231_zreYFeI65dHb" title="Accrued expenses reclassified amount">72,000</span> of return reserves previously reflected as an offset to accounts receivable at December 31, 2023 to accrued expenses to conform to current period classification.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"></p>
CY2023Q4	brgx	Accrued Expenses Reclassified Amount AccruedExpensesReclassifiedAmount	72000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	143924	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	217529	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	143924	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	217529	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5162	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	62467	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	108653	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	142685	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113815	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205152	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	143924	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	217529	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5162	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	62467	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	108653	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	142685	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113815	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205152	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5162	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	62467	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	108653	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	142685	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113815	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205152	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5162	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	62467	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	142685	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	113815	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205152	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	49363	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1059860	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10233776	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	569730	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1059860	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1002281	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2248355	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2248355	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2248355	usd
CY2024Q2	brgx	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	238076	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11293636	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	49363	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10233776	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49363	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	569730	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1059860	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1002281	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2248355	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2248355	usd
CY2024Q2	brgx	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	238076	usd
CY2024Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7642	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1194	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11293636	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	49363	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10233776	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49363	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	569730	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1059860	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1002281	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2248355	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2248355	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2248355	usd
CY2024Q2	brgx	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	238076	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1194	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-1059860	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10233776	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	569730	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1059860	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1002281	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2248355	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2248355	usd
CY2024Q2	brgx	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	238076	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1194	usd
CY2024Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7642	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1194	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2024Q2	brgx	Warrants Exercisable WarrantsExercisable	0	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2024Q2	brgx	Warrants Exercisable WarrantsExercisable	0	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2024Q2	brgx	Warrants Exercisable WarrantsExercisable	0	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	1100412	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	1100412	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	525681	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	525681	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	850813	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	850813	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	375681	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	375681	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	249599	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	249599	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2024Q2	brgx	Warrants Exercisable WarrantsExercisable	0	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	1100412	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	525681	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	525681	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	850813	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	850813	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	375681	usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent	375681	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	249599	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	249599	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	150000	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	150000	usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	150000	usd
CY2024Q2	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	995294	usd
CY2023	us-gaap	Interest Expense InterestExpense	292190	usd
CY2024Q2	us-gaap	Payments For Rent PaymentsForRent	5175	usd
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	5175	usd
CY2024Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	2975	usd
CY2023Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	3374	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	5536	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	7325	usd
	us-gaap	Legal Fees LegalFees	5000	usd
	us-gaap	Legal Fees LegalFees	53189	usd
CY2023	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	213516	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	150000	usd
CY2024Q2	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	995294	usd
CY2023Q4	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	963215	usd
CY2023	us-gaap	Interest Expense InterestExpense	292190	usd
CY2024Q2	us-gaap	Payments For Rent PaymentsForRent	5175	usd
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	5175	usd
	us-gaap	Payments For Rent PaymentsForRent	10350	usd
	us-gaap	Payments For Rent PaymentsForRent	10350	usd
CY2024Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	2975	usd
CY2023Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	3374	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	5536	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	7325	usd
	us-gaap	Legal Fees LegalFees	5000	usd
	us-gaap	Legal Fees LegalFees	53189	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	196517	usd
CY2023	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	213516	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	brgx	Notes Payable And Loans Related Parties Current NotesPayableAndLoansRelatedPartiesCurrent	995294	usd
CY2024Q2	us-gaap	Payments For Rent PaymentsForRent	5175	usd
CY2023Q2	us-gaap	Payments For Rent PaymentsForRent	5175	usd
	us-gaap	Payments For Rent PaymentsForRent	10350	usd
CY2024Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	2975	usd
CY2023Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	3374	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	5536	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	7325	usd
	us-gaap	Legal Fees LegalFees	5000	usd
	us-gaap	Legal Fees LegalFees	53189	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	196517	usd
CY2023	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	213516	usd
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
	us-gaap	Payments For Rent PaymentsForRent	10350	usd
	us-gaap	Payments For Rent PaymentsForRent	10350	usd
CY2024Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	2975	usd
CY2023Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	3374	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	5536	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	7325	usd
	us-gaap	Legal Fees LegalFees	5000	usd
	us-gaap	Legal Fees LegalFees	53189	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	196517	usd
CY2023	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	213516	usd
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-007026-index-headers.html	Edgar Link	pending
0001683168-24-007026-index.html	Edgar Link	pending
0001683168-24-007026.txt	Edgar Link	pending
0001683168-24-007026-xbrl.zip	Edgar Link	pending
bioregenx_ex0401.htm	Edgar Link	pending
bioregenx_ex0402.htm	Edgar Link	pending
bioregenx_ex1001.htm	Edgar Link	pending
bioregenx_ex3100.htm	Edgar Link	pending
bioregenx_ex3200.htm	Edgar Link	pending
bioregenx_i10q-063024.htm	Edgar Link	pending
brgx-20240630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
brgx-20240630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bioregenx_i10q-063024_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
brgx-20240630_cal.xml	Edgar Link	unprocessable
brgx-20240630_lab.xml	Edgar Link	unprocessable
brgx-20240630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRGX
BIOREGENX, INC. Stock $brgx

2024 Q3 Form 10-Q Financial Statement

#000168316824007026 Filed on October 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRGX BIOREGENX, INC. Stock $brgx

2024 Q3 Form 10-Q Financial Statement

#000168316824007026 Filed on October 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRGX
BIOREGENX, INC. Stock $brgx